A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames
about
A new antigen recognized by cytolytic T lymphocytes on a human kidney tumor results from reverse strand transcriptionNY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimensTrypanosoma cruzi adjuvants potentiate T cell-mediated immunity induced by a NY-ESO-1 based antitumor vaccineImmunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine.A processed pseudogene codes for a new antigen recognized by a CD8(+) T cell clone on melanoma.T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product.Clinical applications of a peptide-based vaccine for glioblastoma.HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancerProgress in the development of immunotherapy for the treatment of patients with cancer.Development of effective immunotherapy for the treatment of patients with cancer.Non-conventional sources of peptides presented by MHC class I.Induction of a specific CD8+ T-cell response to cancer/testis antigens by demethylating pre-treatment against osteosarcomaThe melanoma antigens MELOE-1 and MELOE-2 are translated from a bona fide polycistronic mRNA containing functional IRES sequences.CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production.Current advances in T-cell-based cancer immunotherapyMonitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses.NY-ESO-1 expression in hepatocellular carcinoma: A potential new marker for early recurrence after surgeryEnhanced Recognition of HIV-1 Cryptic Epitopes Restricted by HLA Class I Alleles Associated With a Favorable Clinical Outcome.Tumor cell programmed death ligand 1-mediated T cell suppression is overcome by coexpression of CD80Measures for the degree of overlap of gene signatures and applications to TCGA.HLA-DRB1 allele polymorphisms in genetic susceptibility to esophageal carcinoma.Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectorsIdentification of a mutated fibronectin as a tumor antigen recognized by CD4+ T cells: its role in extracellular matrix formation and tumor metastasis.Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells.Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes.Death of a dogma: eukaryotic mRNAs can code for more than one protein.Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules.Mobilizing the low-avidity T cell repertoire to kill tumors.Identification of BING-4 cancer antigen translated from an alternative open reading frame of a gene in the extended MHC class II region using lymphocytes from a patient with a durable complete regression following immunotherapyRecombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans.Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling.Usage of cancer associated autoantibodies in the detection of diseaseLV305, a dendritic cell-targeting integration-deficient ZVex(TM)-based lentiviral vector encoding NY-ESO-1, induces potent anti-tumor immune response.Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele.Prevalence of plasma autoantibody against cancer testis antigen NY-ESO-1 in HTLV-1 infected individuals with different clinical statusIdentification of Melanoma-reactive CD4+ T-Cell Subsets From Human Melanoma Draining Lymph Nodes.Immune targets and neoantigens for cancer immunotherapy and precision medicine.Correlation of high and decreased NY-ESO-1 immunity to spontaneous regression and subsequent recurrence in a lung cancer patient.An alternative open reading frame of the human macrophage colony-stimulating factor gene is independently translated and codes for an antigenic peptide of 14 amino acids recognized by tumor-infiltrating CD8 T lymphocytes.A special issue on cancer immunotherapy.
P2860
Q22010943-C5FAC206-A80F-4B81-84C9-16BBAA84F1F2Q24649090-959405F4-B126-460C-85AB-D822F30FFB07Q28483146-83F5BEA9-422F-4358-B44C-DCE8BD567D55Q30371547-FA283DDF-B229-4329-958B-9FD08A8D05CBQ30865419-EA72664E-C6F5-4786-9576-D768525B9DA7Q33202641-56E47B09-2E0E-4FED-BE63-0EB95C7DEE7FQ33668575-C15C26CD-3922-4033-A51B-436F09869F32Q33909892-B5A75355-97E6-474B-BB60-646CA91A1B0AQ34570245-3D773ED6-A6C6-4698-B8CD-2E326FB6ACC8Q34647354-6F63FD96-98C7-4538-87C1-B9F7B103E202Q34768462-460A3BC7-DB9B-4417-BC46-31CC0105055CQ34786566-5054F41E-0E75-40F8-9157-7EEB335FEFA2Q35005458-64B96F2B-57D1-4F0F-8F87-C6DCEE5A470AQ35048637-1EE06782-3C86-4509-90C6-86BE41EFD860Q35215158-99A70D97-4D7F-41B1-BA20-E226246AE0B5Q35693584-19D21C30-584B-4BA8-AFE9-D28751DC101DQ35995828-7E16D7D9-2E1E-4937-9F10-954A97151DD7Q36015624-F4B5D059-1DC3-40BA-AEFD-E770A1543E4AQ36039709-ADB6C30F-1716-42B6-BD2E-6F63EF573BF8Q36060588-9862BCBF-BEB9-4689-B04E-2767DB589D0AQ36209671-9895E9C1-2747-4100-A654-F77CADCF898CQ36327106-4F23B3B0-276A-420D-98C8-B62A1549605FQ36369709-61EDC65F-AC0B-476B-A9E4-DD70E4E9D42AQ36369960-D3C9C655-D1D4-4FEE-A12A-24A409ABB2D5Q36399240-B5340B03-4634-47CE-9303-2BD255467A5FQ36443272-9F063EAD-4A2A-4BE5-9E4C-EE8F99F4B732Q36456744-B141335D-3630-428D-B162-3EDD13F965AAQ36891310-E30F555A-694B-4768-82A0-65B81A62EF19Q36908561-51808CA4-E5FB-4098-A655-A188523C096CQ36986730-0471EFC6-BF56-40AA-BDF6-BFF02B7EF374Q37139813-086C029F-72CC-4E6D-A236-4A43255EC020Q37217734-25E057F6-9076-42CE-8EDF-0A4C8EDD46B2Q37225212-C230C64D-B549-4C1D-862F-F133ABF12836Q37266210-619CE104-A6AC-4B85-ABE2-8AF742EC4FE4Q38675283-E41600B5-15CF-4EFE-BBE6-0A0053AB4476Q38814049-96FAE508-7E0F-42BD-80EA-5F0219A0FA3FQ39057617-A5B20A45-6552-4FC2-97D1-7C6A7889252FQ41836087-C9F1AF3D-0A26-409F-9A2E-AB01770BAC94Q42058413-EE5DF428-EE1F-4EE1-884C-C24709B9834FQ53591514-56123328-070C-40DC-9D63-E983B7AA012D
P2860
A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames
description
1998 nî lūn-bûn
@nan
1998 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
A breast and melanoma-shared t ...... different open reading frames
@ast
A breast and melanoma-shared t ...... different open reading frames
@en
A breast and melanoma-shared t ...... different open reading frames
@nl
type
label
A breast and melanoma-shared t ...... different open reading frames
@ast
A breast and melanoma-shared t ...... different open reading frames
@en
A breast and melanoma-shared t ...... different open reading frames
@nl
prefLabel
A breast and melanoma-shared t ...... different open reading frames
@ast
A breast and melanoma-shared t ...... different open reading frames
@en
A breast and melanoma-shared t ...... different open reading frames
@nl
P2093
P3181
P1476
A breast and melanoma-shared t ...... different open reading frames
@en
P2093
Johnston SL
Rosenberg SA
Schwartzentruber DJ
Topalian SL
P304
P3181
P407
P577
1998-10-01T00:00:00Z